Jeffrey B. Kindler, J.D.

Jeffrey B. Kindler has more than three decades of business experience and has held leadership positions at some of the world’s most recognized companies. Mr. Kindler has served as an operating partner of ARTIS Ventures, a venture investment firm, since January 2020, Senior Advisor to Blackstone, an investment firm, since June 2020, and as the Chief Executive Officer of Centrexion Therapeutics, a private biopharmaceutical company, since October 2013.. Prior to joining Centrexion, Mr. Kindler was the Chairman and CEO of Pfizer Inc., a leading pharmaceutical company. As CEO, he led Pfizer’s $68 billion merger and acquisition of Wyeth, diversified its product portfolio, improved its research and development pipeline, and reshaped the company’s commercial, innovation and leadership models to drive growth and cultural change. Mr. Kindler has served on the board of directors of Perrigo Company plc since February 2017 and Precigen, Inc. since November 2011, all publicly-traded companies. Mr. Kindler previously served on the board of vTv Therapeutics Inc., a publicly-traded biotechnology company, from July 2015 to December 2020, PPD, Inc. from March 2012 until its acquisition by Thermo Fisher Scientific, Inc. in December 2021, and SIGA Technologies, Inc., a publicly-traded pharmaceutical company, from March 2013 to June 2020.Mr. Kindler holds a B.A. from Tufts University and a J.D. from Harvard University.